menu
    • menu
    [{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sosei Group Corporation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-1117570","moa":"M1\/M4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Aditum Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Aditum Bio"},{"orgOrder":0,"company":"Ciitizen","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Ciitizen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ciitizen \/ Praxis Precision Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Ciitizen \/ Praxis Precision Medicines"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NBI-1117570

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sosei Heptares Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-11175...

                            Details : NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.

                            Product Name : NBI-1117570

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : NBI-1117570

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Neurocrine Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eisai

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Eisai

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : BioArctic AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of...

                            Details : Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerat...

                            Product Name : Leqembi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : BioArctic AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sosei Group Corporation

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QP50ESO5RA

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Biohaven Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Bioh...

                            Details : The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subj...

                            Product Name : HTL0022562

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 23, 2021

                            Lead Product(s) : QP50ESO5RA

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Biohaven Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HTL0018318

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Allergan Aesthetics

                            Deal Size : $3,290.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

                            Details : AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the ...

                            Product Name : HTL0018318

                            Product Type : Other Small Molecule

                            Upfront Cash : $125.0 million

                            May 01, 2021

                            Lead Product(s) : HTL0018318

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Allergan Aesthetics

                            Deal Size : $3,290.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ciitizen

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Ciitizen

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relutrigine

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Praxis Precision Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development

                            Details : Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN...

                            Product Name : PRAX-562

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : Relutrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Praxis Precision Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asahi Kasei Pharma

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Asahi Kasei Pharma

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AK1780

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $410.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

                            Details : Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.

                            Product Name : AK1780

                            Product Type : Other Small Molecule

                            Upfront Cash : $20.0 million

                            January 29, 2021

                            Lead Product(s) : AK1780

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $410.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMP-301

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Aditum Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases

                            Details : Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design ...

                            Product Name : TMP-301

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 11, 2020

                            Lead Product(s) : TMP-301

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Aditum Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth